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Abstract: Cyclotides are plant mini-proteins whose natural function is thought to be to 
protect plants from pest or pathogens, particularly insect pests. They are approximately  
30 amino acids in size and are characterized by a cyclic peptide backbone and a cystine 
knot arrangement of three conserved disulfide bonds. This article provides an overview  
of the reported pesticidal or toxic activities of cyclotides, discusses a possible common 
mechanism of action involving disruption of biological membranes in pest species, and 
describes methods that can be used to produce cyclotides for potential applications as novel 
pesticidal agents. 
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1. Introduction  
Cyclotides [1] are a plant-derived family of small proteins characterized by their head-to-tail cyclic 
backbone and a cystine knot arrangement of three conserved disulfide bonds. They were first 
discovered in plants from the Rubiaceae (coffee) and Violaceae (violet) families but have since been 
reported in a range of other plants from the Cucurbitaceae (cucurbit) and Fabaceae (legume) families 
and it has been predicted that they are widely distributed within the plant kingdom [2]. Cyclotides are 
notable for their exceptional stability and their diverse range of bioactivities, as well as for their 
expression in a wide range of plant tissues, including leaves, stems, flowers, dormant seeds and   
roots [3]. There have been a number of recent reviews on the discovery [4–6], structures [4,7,8], and 
applications [9–12] of cyclotides, to which the reader is referred for more background but here the 
focus is on their pesticidal and/or toxic activities. 
The structure of the prototypical cyclotide, kalata B1, is shown in Figure 1 [13], highlighting that 
cyclotides are around 30 amino acids in size with a cyclic peptide backbone. They fold into compact 
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three-dimensional shapes that incorporate a small β-sheet structure and a series of turns built around 
the cystine knot core. This compact structure and elaborate cross-bracing by disulfide bonds is a main 
contributing factor that makes cyclotides exceptionally stable. They are highly resistant to chemical, 
thermal and enzymatic treatments that would typically destroy conventional proteins [14]. 
Figure 1. Schematic illustration of (a) the sequence and (b) the structure of the prototypical 
cyclotide, kalata B1 showing the head-to-tail cyclic backbone and six conserved cysteine 
residues (numbered using Roman numerals) that are connected together in a I–IV, II–V and 
III–VI connectivity leading to a cystine knot [15]. This connectivity has been established 
by a range of chemical and NMR methods [16,17]. The structure folds up into a compact 
three-dimensional shape that contains a β-sheet motif (indicated by the broad arrows) as well 
as a series of turns. The backbone segments between cysteine residues are referred to as 
loops and are numbered 1–6. Some loops, e.g. loops 1 and 4, are relatively highly conserved, 
whereas others are typically hypervariable in cyclotides from different plants, leading to  
the description of cyclotides as a natural combinatorial template [18]; (c) Space-filling 
view of the surface of kalata B1 showing the location of a surface-exposed patch of 
hydrophobic residues. 
 
Individual plants express a suite of cyclotides, sometimes comprising more than 100 different 
sequences. Based on the reported discovery rates for cyclotides in the Violaceae and Rubiaceae and  
the large number of unique cyclotides per plant species it has been predicted that there might be 
~50,000 cyclotide sequences in nature [2] but this is probably an underestimate based on recent 
discoveries in the Fabaceae [19,20]. Table 1 shows a representative selection of cyclotides from the 
three major subfamilies that have so far been identified. The Möbius and bracelet subfamilies are the 
largest subfamilies of cyclotides and are so named because of the presence or absence of a conceptual 
180° twist in the peptide backbone brought about by a cis X-Pro peptide bond in the Möbius class and 
the lack of this “twist” in the circular ribbon of the bracelet class [1]. A smaller subfamily of cyclotides Toxins 2012, 4                             
 
 
141
known as the trypsin inhibitor cyclotides has quite different sequences than the other two subfamilies 
and is also routinely classified as “cyclic knottins” based on their sequence homology to conventional 
(acyclic) cystine knot proteins from the knottin family [21]. The cyclotides shown in Table 1 have been 
structurally characterized and their relevant PDB ID codes are given in the table, along with their 
sequences and some biophysical characteristics, including net charge and size (numbers of amino acids). 
Table 1. Representative cyclotides from the Möbius, bracelet and trypsin inhibitor subfamilies. 
Cyclotide 
a AA 
b Ch 
c Sequence 
d PDB 
e Ref. 
Möbius subfamily 
kalata B1  30  +2  GLPVCGETCVGGTCNTPGCTCSWPVCTRN 1NB1 [13] 
kalata B2  29  −1  GLPVCGETCFGGTCNTPGCSCTWPICTRD 1PT4 [22,23] 
kalata B7  29  +1  GLPVCGETCTLGTCYTQGCTCSWPICKRN  2JWM [24] 
kalata B12  28  −2  GSLCGDTCFVLGCNDSSCSCNYPICVKD  2KVX [25] 
cycloviolacin O14  31  +3  GSIPACGESCFKGKCYTPGCSCSKYPLCAKN 2GJ0 [26] 
varv F  29  0  GVPICGETCTLGTCYTAGCSCSWPVCTRN  3E4H [27] 
Bracelet subfamily 
circulin A  30  +2  GIPCGESCVWIPCISAALGCSCKNKVCYRN  1BH4 [28,29] 
circulin B  31  +2  GVIPCGESCVFIPCISTLLGCSCKNKVCYRN 2ERI [29] 
cycloviolacin O1  30  0  GIPCAESCVYIPCTVTALLGCSCSNRVCYN  1NBJ [26] 
cycloviolacin O2  30  +2  GIPCGESCVWIPCISSAIGCSCKSKVCYRN 2KNM [26] 
kalata B5  30  −1  GTPCGESCVYIPCISGVIGCSCTDKVCYLN 2KUX [30,31] 
kalata B8  31  +1  GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD  2B38 [32] 
tricyclon A  33  −1  GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN  1YP8 [33] 
palicourein 37  −1  GDPTFCGETCRVIPVCTYSAALGCTCDDRSDGLCKRN  1R1F [34,35] 
vhl-1 31  0  SISCGESCAMISFCFTEVIGCSCKNKVCYLN 1ZA8 [36] 
vhl-2 30  −1  GLPVCGETCFTGTCYTNGCTCDPWPVCTRN  2KUK [36,37] 
vhr1 30  0  GIPCAESCVWIPCTVTALLGCSCSNKVCYN  1VB8 [3] 
Trypsin inhibitor subfamily 
MCoTI-II 34  +3  GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD  1IB9 [38,39] 
a Selected examples only are shown. For a full listing of cyclotides see CyBase [40];   
b AA refers to the number of amino acids in the sequence; 
c Ch refers to the net charge of the 
cyclotide; 
d shows the sequences using one-letter amino acid codes, with the conserved Glu (E) 
bolded; 
e PDB ID code for 3D coordinates. 
Cyclotides were originally discovered based on their observed bioactivities. The prototypical 
member of the family, kalata B1, was identified as the active uterotonic agent in a medicinal tea used 
by women in Africa to accelerate child birth. The plant used to make the tea is Oldenlandia affinis, a 
member of the Rubiaceae family of plants [41]. The first cyclotide discovered from the violet family, 
violapeptide 1, was fortuitously discovered while looking for haemolytic activity of saponins [42]. In one 
of the most significant early reports, a series of circular peptides was discovered in a screening program 
searching for anti-HIV molecules [29,43,44]. Similarly, cyclopsychotride A [45] was discovered during a 
screen for neurotensin antagonists. These initial bioassay-guided discoveries led to systematic searches 
for cyclotides based on their structural properties and this eventually led to the discovery of a wide range 
of other activities for cyclotides, including antimicrobial [46], insecticidal [22,47] and other pesticidal Toxins 2012, 4                             
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activities. I will describe these biological activities in more detail in Section 3, after making some brief 
comments on the biosynthesis and artificial synthesis of cyclotides. 
Cyclotides are biosynthesized ribosomally as precursor proteins that encode one or more cyclotide 
domains [48,49]. Figure 2 shows the generic arrangement of a typical cyclotide precursor protein, which 
comprises an endoplasmic reticulum (ER) signal sequence, a pro-domain, a mature cyclotide domain and 
a C-terminal region. Although the excision and cyclization processes that yield cyclic mature peptides 
from these precursors are not fully understood, it is believed that asparaginyl endoproteinase (AEP) 
enzyme activity plays an important role [50,51]. This hypothesis is consistent with the presence of an 
absolutely conserved Asn (or Asp) residue that at the C-terminus of the cyclotide domain within the 
precursor proteins. (e.g., see cyclotide sequences in Table 1). It is further supported by studies involving 
expression of mutated cyclotides in transgenic plants that have identified residues important for 
processing. For example mutation of the conserved Asn to Ala abolishes production of cyclic peptides 
in planta [51]. 
Figure 2. Schematic illustration of the architecture of cyclotide precursor proteins from the 
Violaceae and Rubiaceae. They comprise an ER signal sequence, an N-terminal prodomain, 
the mature peptide sequence and a C-terminal pro-peptide. Some precursors contain multiple 
copies (i.e., up to three copies) of the cyclotide domain flanked by short pro-peptide regions. 
Recent studies of cyclotides from the Fabaceae family have suggested that they are 
produced from what appears to be an ancestral albumin gene [20,52], suggesting that plants 
have evolved several alternative mechanisms for the biosynthesis of cyclotides. 
 
2. Pesticidal and/or Toxic Activities 
The natural function of cyclotides is thought to be for the protection of plants against pests, a 
suggestion prompted by the discovery that cyclotides potently inhibit the growth and development of 
certain insect larvae [47]. It is not known why an individual plant species can express so many different 
cyclotides. This phenomenon might have evolved to counter the development of resistance of pests to 
an individual defense molecule, or it might reflect that fact that cyclotides have an array of functions in 
plants that have so far not been identified. For example, some host defense peptides in animals have 
direct antimicrobial activity but also function as signaling molecules and immune modulators. Similar 
multifunctional roles might be possible for cyclotides but have so far not been reported. In this article 
the focus is on toxic activities of cyclotides. Table 2 summarizes examples of pesticidal and/or toxic 
activities of cyclotides. They include hemolytic, cytotoxic, antimicrobial, insecticidal, antifouling, 
molluscicidal and nematocidal activities. Toxins 2012, 4                             
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Table 2. Pesticidal and/or toxic activities reported for selected cyclotides. 
Cyclotide Activity Ref. 
Möbius subfamily 
kalata B1  Insecticidal, molluscicidal, hemolytic, nematocidal, antibacterial, anti-HIV  [47,53–56] 
kalata B2  Insecticidal, molluscicidal, nematocidal, antibacterial  [22,56,57] 
kalata B5  Molluscicidal  [56] 
cycloviolacin O14  Nematocidal, anti-HIV, hemolytic  [26] 
varv A & F  Cytotoxic  [27,58] 
Bracelet subfamily 
circulin A & B  Hemolytic, anti-bacterial, anti-HIV  [29] 
cycloviolacin O1  Nematocidal, molluscicidal  [26,56,59,60] 
cycloviolacin O2  Nematocidal, cytotoxicity, hemolytic, anti-barnacle, antibacterial  [57,61] 
Cycloviolacin Y1  Hemolytic, anti-HIV  [62] 
vhl-1 Nematocidal,  anti-HIV  [36] 
Trypsin inhibitor subfamily 
MCoTI-II Protease  inhibition  [63–65] 
2.1. Hemolytic and Cytotoxic Activities 
Hemolytic activity, i.e., the ability to cause lysis of erythrocytes, was one of the first activities 
reported for cyclotides and indeed led to the discovery of violapeptide-I [42]. Overall, cyclotides are 
only mildly hemolytic, with median hemolytic doses (HD50 values) of 10–1000 μM [66] which is weak 
compared to the potent hemolytic agent melittin from bee venom with a HD50 of ~1 μM. Interestingly, 
hemolytic activity is lost on linearization of cyclotides [67], showing that the intact cyclic backbone  
is important for this activity, as also appears to be the case for a number of other cyclotide activities, 
including anti-HIV activity. 
So far there have been no reports describing a functional role for this hemolytic activity in a specific 
host defense interaction. Most investigations of the hemolytic activity of cyclotides have been more 
concerned with engineering out this activity for cases where a cyclotide framework is targeted for use as 
a pharmaceutical template. For example, an alanine scan identified a region of the kalata B1 surface in 
which substitution of any one of nine resides with Ala significantly reduced the hemolytic activity [68]. 
Various cyclotides have been reported to be cytotoxic to other human cell lines aside from 
erythrocytes. Cycloviolacin O2, a bracelet cyclotide, has been a particular focus of these studies and of 
most interest is a small degree of selective toxicity to cancer cell lines relative to normal cells, opening 
the possibility of uses of cyclotides in anti-cancer activity [58,69–71]. This activity however did not 
hold-up to be useful in a mouse tumor model [72]. The reasons for a lack of in vivo activity are not 
fully understood, but could include high clearance rates or poor distribution to the site of action in a 
poorly vascularized tumor model [72]. Also of concern from a pharmaceutical perspective is the 
finding that cycloviolacin O2 has a very abrupt toxicity profile, with lethality in mice at a single 
injection of 2 mg/kg but no signs of discomfort to the animals at 1.5 mg/kg [72]. 
Overall the cytotoxic activities of cyclotides appear to be confined to members of the Möbius   
and bracelet subfamilies and toxic activities have not been reported for members of the trypsin 
inhibitor subfamily. Toxins 2012, 4                             
 
 
144
2.2. Antimicrobial Activity 
Antimicrobial activity of several synthetically produced cyclotides was first reported in 1999 [46] 
and there have only been a few other primary reports of this activity since then [20,73,74]. Overall, it 
appears that not all cyclotides are antimicrobial and that the positive examples have activity typically 
only under low salt conditions. In the initial study [46] four synthetically produced cyclotides,   
kalata B1, circulin A, circulin B and cyclopsychotride A, were tested against a range of human 
pathogenic bacteria, including E. coli and Staphylococcus aureus. The most potent example was 
circulin A against S. aureus, which had a minimum inhibitory concentration (MIC) of 0.19 µM, but 
kalata B1 was also reported to be highly potent (MIC = 0.26 µM) against S. aureus. Kalata B1 was 
inactive against E. coli under either high or low salt conditions but a later study reported conflicting 
data in E. coli. [73] Recent studies have confirmed antimicrobial activity for cycloviolacin O2, [74] 
and hedyotide B1 [20]. These studies have focused on testing against human pathogenic bacteria and it 
appears that there have been no systematic studies of the effect of cyclotides on plant-pathogenic 
bacteria. A recent report [57] did however examine the toxic effects of cyclotides against soil bacteria, 
and against several plants and algae, to determine the environmental effects of cyclotides, as further 
described in Section 6. 
2.3. Insecticidal Activity 
The first report of insecticidal activities of cyclotides was in 2001 where kalata B1 was shown to 
inhibit the growth and development and increase the mortality of Helicoverpa larvae presented with an 
artificial diet containing cyclotides [47]. When present in a diet at approximately the same concentration 
as it occurs in natural leaf tissue (~0.8 µmol/g), kalata B1 was found to be a potent insecticidal agent. 
These findings have since been reproduced in studies of kalata B2 [22] from O. affinis and Cter M 
from Clitoria ternatea. [19]. The mechanism of the insecticidal activity appears to be by disruption of 
the mid-gut membranes of larvae that have ingested cyclotides, as judged from electron microscopy 
studies [75]. Although insecticidal activity is presumed to be the primary natural biological function of 
cyclotides [76] there have not yet been systematic reports of their testing against a range of insect 
species, nor have there been studies of possible synergistic effects of cyclotides, given that a single 
plant often expresses a large number of cyclotides in any one tissue [12]. 
2.4. Anti-Fouling Activities 
Cycloviolacin O2 has been reported to have activity against the barnacle Balanus improvisus in the 
sub-micromolar range [61]. Although there potentially could be applications of this activity in defouling 
ship hulls, the cost of cyclotides is likely to be a limiting factor in precluding such applications, unless 
considerably cheaper production methods for cyclotides can be developed than are currently available.  
It is interesting that cycloviolacin O2 is a member of the bracelet subfamily of cyclotides and that in 
general this subfamily tends to be more active in toxic properties against many organisms relative to 
the Möbius subclass. Toxins 2012, 4                             
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2.5. Molluscicidal Activities 
Cyclotides tested against Pomacea canaliculata, the Golden Apple snail, a major pest of rice in 
South East Asia have shown promising activities. This snail was originally imported into Taiwan from 
South America in the 1980s and has now spread widely in agricultural wetlands in Japan, the Philippines 
and Taiwan where it has caused crop damage estimated to have cost billions of dollars. The cyclotides 
cycloviolacin O1, kalata B1 and kalata B2 were found to be more toxic to Pomacea canaliculata than  
the commercially used molluscicide metaldehyde, whereas kalata B7 and B8 were significantly less  
toxic [56]. These assays showed that there was a dose dependent effect on snail mortality when 
cyclotides were introduced into the aquatic environment of the snails. The LC50 (median lethal 
concentration) was 53 µM for kalata B2 and 133 µM for metaldehyde. Tests of kalata B2 against a 
non-target fish species, Oreochromis niloticus, which has been used as a biological control agent in 
rice fields, revealed toxicity lower than rotenone, a naturally occurring commercial piscicidal agent. 
However, further detailed investigations on the relative toxicities of cyclotides against target and   
non-target species are required before cyclotides could be used to develop natural molluscicides. 
2.6. Nematocidal Activities 
The nematocidal activity of cyclotides has been extensively studied over the last few years, 
particularly against livestock pest nematodes [55,59,60]. In the first study [55] the in vitro effects of 
kalata B1, B2, B3, B5, B6 and B7 on the viability of egg, larval, and adult life stages of two species of 
economically important gastrointestinal nematode parasites of livestock, Hemonchus contortus and 
Trichostrongylus colubriformis were examined. The cyclotides showed significant activity in 
inhibiting development of nematode larvae and motility of adult worms, with activities comparable to 
some commercially used anthelmintic compounds. For example, kalata B6 was the most potent of the 
natural cyclotides tested, having a larvicidal activity (IC50) of 2.6 µg/mL against H. contortus. [55]. 
Alanine mutants of kalata B1 were assayed against larvae to determine residues responsible for activity 
and it was found that the anthelmintic activity was dramatically reduced as a consequence of the 
mutation of a series of residues clustered on one face of the molecule. Activities toward larvae were 
equivalent in the naturally occurring L-isomer of kalata B1 and a synthetic all-D-isomer, indicating 
that there is no chiral requirement for anthelmintic activity [55]. The clustering of “bioactive” residues 
and the lack of chiral selectivity supported a proposed mode of action of cyclotides that involves a 
membrane-based interaction rather than interaction with a stereospecific receptor. The cyclotide-induced 
leakage of a fluorescent dye from vesicles used as a model membrane mimetic further confirmed   
the membrane lytic ability of cyclotides. The relative potency of kalata B1 and kalata B2 in causing 
membrane leakage was consistent with the order of their anthelmintic activity. 
This initial study was followed by a series of investigations that led to improved anthelmintic 
activity against these livestock pests [59,77], and also demonstrated activity against canine and human 
hookworms [60]. Overall, the results demonstrate that the cyclotides show potential for use in the 
control of nematode parasites of both agricultural and medical importance. Toxins 2012, 4                             
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3. Mechanisms of Action 
Although the range of biological activities of cyclotides might seem diverse, in fact they all appear 
to be accounted for by a common mechanism involving interactions of cyclotides with membranes  
and their subsequent disruption. In an early biophysical study NMR chemical shifts and diffusion 
measurements were used to demonstrate a specific interaction between a model membrane in the   
form of dodecylphosphocholine (DPC) micelles and the cyclotide kalata B1 [78]. This was followed by 
similar studies on B7 [79], which confirmed that a hydrophobic patch on the surface of the cyclotides 
(shown in Figure 1c) was the primary interaction face with membranes. The orientation of kalata B1 
binding to the DPC surface is shown in Figure 3a. The precise orientation varies with different 
cyclotides, dependent on the location of the surface-exposed hydrophobic patch [80]. 
Independent studies showed that the membrane binding was functional, in that cyclotides were  
able to induce leakage of contents from phospholipid vesicles (Figure 3b) and form large pores in  
lipid bilayers [81], and that membrane binding modulated cytotoxicity [69]. Surface plasmon 
resonance studies [82,83] also established a specific interaction between cyclotides and phospholipid 
bilayers, as shown in Figure 3c [83]. These various studies have provided details on the selectivity  
of particular cyclotides for particular lipid subtypes. Overall, cyclotides appear to have a preference  
for phosphatidylethanolamine (PE) as opposed to phosphatidylcholine lipids (PC). Furthermore, for 
membranes of a given PE content kalata B1 has a higher affinity for membranes in a liquid disordered 
phase (i.e., more rigid membranes rich in cholesterol (Chol) and sphingomyelin (SM) that are raft-like 
domains [83]). 
Figure 3. Schematic illustration of studies done to establish membrane binding of 
cyclotides. Panel (a) shows preferred binding mode of kalata B1 to DPC micelles as 
deduced from NMR studies, indicating binding via the hydrophobic patch [78,80];   
(b) shows vesicle leakage studies in which the addition of cyclotides to phospholipid 
vesicles causes leakage of vesicle contents in a dose dependent manner, with differential 
effects for different lipid compositions made up of palmitoyloleoylethanolamine (POPC), 
palmitoyloleoylethanolamine (POPE), cholesterol (Chol) and sphingomyelin (SM) [83];  
(c) shows surface plasmon resonance studies indicating preferential binding to PE compared 
to PC lipids [83]. 
 
The ability to chemically synthesize or modify cyclotides has been important in establishing 
structure-activity relationships. As noted earlier, chemically modified cyclotide derivatives in which 
individual residues are successively replaced by alanine established that there was a patch of residues 
clustered on the surface of cyclotides that is important for biological activity [68]. This bioactive patch Toxins 2012, 4                             
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is not co-located with the hydrophobic patch implicated in membrane binding, which led to the 
suggestion that self-association may be involved in the mediation of cyclotide activity. Chemical 
modification studies have also established the importance of a key glutamic acid in regulating the 
activity of cyclotides. Esterification of this residue causes a marked drop in biological activity [84]. 
This residue is at the centre of the bioactive patch of residues on the kalata B1 cyclotide surface. The 
Glu residue is conserved in all but one of the currently known naturally occurring cyclotides, with the 
exception being kalata B12, where it is replaced with the conservative Asp residue. However, the 
precise role of the Glu in determining cyclotide activity is yet to be delineated. 
In another example of the value of chemistry in determining structure-activity relationships of 
cyclotides a recent study used a chemically synthesized all-D kalata molecule to confirm the membrane 
binding hypothesis [83]. The insecticidal, anti-HIV and hemolytic activity of all-D and all-L mirror 
image forms of kalata B1 were similar, suggesting that a stereospecific receptor is not involved in   
the interaction. The slightly lower activity for the all-D peptide can be attributed to the slight chirality 
associated with membranes. 
In summary, although cyclotides have a diverse range of activities, including antimicrobial, anti-HIV 
and hemolytic, and insecticidal, all these activities can be attributed to membrane binding interactions. In 
the case of insecticidal activity electron microscopy studies have shown clear disruption to the surface 
cells in the midgut of Lepidopteran larvae fed on a cyclotide-containing diet [75]. 
4. Methods of Production of Cyclotides 
To commercially exploit cyclotides as pesticidal agents it will be necessary to develop cost-effective 
approaches for delivering them to target plants. Synthetic methods to produce cyclotides have been 
developed over the last decade, and include solid phase peptide synthesis approaches [46,85–88] as 
well as chemo-enzymatic [64,65,89,90] and biological approaches involving modified inteins [91–93]. 
So far, most of the proof-of-concept work on the structure-activity relationships of cyclotides has been 
done using chemically synthesized cyclotides analogues. Solid phase chemistry is the preferred method 
here and typically the ligation of the N and the C terminus is achieved using an adaptation of “native 
chemical ligation” chemistry [94,95]. This requires that the peptide chain be assembled linked to the 
resin with a thioester and the linear precursor sequence assembled in such an order that the N-terminal 
residue is a cysteine. This allows a trans-thioesterification reaction to achieve the cyclization, as 
highlighted in Figure 4. 
This technology works well for Möbius trypsin inhibitor subfamily cyclotides although in the past 
the folding of the bracelet cyclotides has been problematic [96]. Several approaches have recently been 
developed to overcome this limitation and further improvement seems likely in the future [97,98]. 
Another approach to making cyclotides is to assemble them as conventional linear peptides and then 
achieve the cyclization enzymatically. This chemo-enzymatic approach can be done by engineering, 
for example, a trypsin active site into the linear cyclotide precursor and using trypsin to achieve the 
ligation. Proof-of-concept for this approach was established early for the cyclic peptide SFTI-I [99] 
and then adapted to the trypsin inhibitor cyclotide MCoTI-II [64,65,89,90]. One advantage of this 
approach is that the enzyme can be immobilized on a column and the cyclization achieved while the 
substrate flows through the column, thus leading to easy purification. Toxins 2012, 4                             
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Figure 4. Schematic illustration of synthetic chemical approach for the production of 
cyclotides. The peptide chain is assembled using solid phase peptide chemistry (SPPS) 
with the C-terminal residue (aa1) linked to the resin using a thioester linker. Amino acids 
are added sequentially and the chain completed with an N-terminal cysteine. Since 
cyclotides contain six cysteines there are thus six possible linear cyclotide designs that 
could be used to produce a given cyclotide [87]. The linear cyclotide is cleaved from the 
solid-phase resin under acidic conditions. Cyclization occurs under basic conditions 
through a trans-esterification reaction and spontaneous S, N-acyl shift. 
 
Biological approaches to cyclotide synthesis have also been developed using E. coli as the host cells 
and modified inteins for activation of linear cyclotide precursors. This approach has been demonstrated 
for a range of cyclotides, including kalata B1 and MCoTI-II and has been used to produce small 
libraries of cyclotides and other cyclic peptides [11,91–93,100,101]. Although at this stage the yields are 
still relatively low compared to solid phase peptide synthesis approaches the biological approach has the 
potential to be less expensive. 
In another biological approach, significant progress has been made in using plant cell culture methods 
for the production of native cyclotides. Specifically, Dörnenburg et al. [102–105] have developed a plant 
cell fermentation system and demonstrated excellent yields of native cyclotides in cultured O. affinis 
cells. Interestingly, the cultured cells not only produced cyclotides that had been identified in whole 
plant extracts of O. affinis but also produced some novel cyclotides not previously seen. Toxins 2012, 4                             
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Despite the promise seen with SPPS or whole-cell-based approaches to cyclotide production, it 
seems likely that for large scale pesticidal applications of cyclotides a transgenic approach in which 
cyclotide genes are inserted directly into target plants is likely to be the most cost effective method. 
The main advantage of this approach is that the cyclotides are expressed only in the target organism 
thus potentially minimizing environmental impacts seen with traditional pesticidal applications 
through spraying. Proof-of-concept that cyclotides can be produced in model plants (tobacco and 
Arabidopsis) has been obtained in studies aimed at understanding the mechanistic basis of cyclotide 
processing [50,51]. 
5. Safety and Breakdown 
The potential applications of cyclotides as pesticidal and/or pharmaceutical agents, merit safely 
evaluations of their effects in the environment. In a recent study [57] it was found that cyclotides were 
toxic to a range of test organisms, with EC50 values ranging from 12 to 140 µM against algae,   
9–40 µM against duckweed, 4–50 µM against lettuce and 7–26 µM against soil bacteria. It was 
concluded that cyclotides might adversely affect solid and aquatic environments and that this should be 
taken into account in future risk assessments for cropping systems producing cyclotides. However, it 
also needs to be noted that cyclotides appear to be widely present naturally in a wide range of plants 
from the Rubiaceae, Violaceae, Cucurbitaceae and Fabaceae families and there are so far no reports of 
toxic effects in the environments associated with these naturally occurring cyclotides. 
There have only been two studies that have reported chemical breakdown products of   
cyclotides [31,84] and it seems that more work in understanding cyclotide turnover is warranted to 
assess how stable these molecules are in their natural environment. 
6. Conclusions 
Although cyclotides were discovered only 15 years ago, they have developed into an exciting field 
of research and display a wide range of biological activities. At this stage it would appear that these 
activities are all associated with membrane interactions and given a demonstrated preference for 
cyclotides for some phospholipids over others it seems likely that cyclotides are targeted to specific 
cell types based on membrane composition to exert their biological activity. The rate of cyclotides 
discovery is rapidly evolving and the prediction of at around 50,000 members of the family may turn 
out to be an underestimate. Significant progress has been made in the chemistry for synthesizing 
cyclotides as well as in their biological synthesis. Thus there are now available an array of tools for the 
chemical production and modification of cyclotides, allowing further refinement of structure-activity 
relationships. Significant progress has also been made in the production of transgenic plants expressing 
cyclotides and so there appears to be great potential for the use of cyclotides as pesticidal agents, and 
indeed for modified cyclotides as medicines. 
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